Journal
CANCER GENETICS
Volume 205, Issue 10, Pages 479-487Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cancergen.2012.06.008
Keywords
Li-Fraumeni syndrome; hereditary cancer predisposition syndrome; TP53 mutations
Categories
Funding
- NIH Office of Rare Diseases Research
- Division of Cancer Control and Population Sciences of the NCI
- intramural research program of the Division of Cancer Epidemiology and Genetics, NCI, NIH
Ask authors/readers for more resources
Li-Fraumeni syndrome (LFS) is a rare dominantly inherited cancer predisposition syndrome that was first described in 1969. In most families, it is caused by germline mutations in the TP53 gene and is characterized by early onset of multiple specific cancers and very high lifetime cumulative cancer risk. Despite significant progress in understanding the molecular biology of TP53, the optimal clinical management of this syndrome is poorly defined. We convened a workshop on November 2, 2010, at the National Institutes of Health in Bethesda, Maryland, bringing together clinicians and scientists, as well as individuals from families with LFS, to review the state of the science, address clinical management issues, stimulate collaborative research, and engage the LFS family community. This workshop also led to the creation of the Li-Fraumeni Exploration (LiFE) Research Consortium.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available